

Australian Gonococcal Surveillance Programme,

1 January to 31 March 2017

Monica M Lahra; Rodney P Enriquez

The World Health Organisation Collaborating Centre for STD and Neisseria Reference Laboratory, South Eastern Area Laboratory Services,

Prince of Wales Hospital, Randwick, NSW, 2031

for The National Neisseria Network, Australia

Introduction

The National Neisseria Network (NNN), Australia comprises reference laboratories in each State and Territory that report data on sensitivity to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The antibiotics are penicillin, ceftriaxone, azithromycin and ciprofloxacin. These are current or potential agents used for the treatment of gonorrhoea. Azithromycin combined with ceftriaxone is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns in Australia and in certain remote regions of the Northern Territory and Western Australia gonococcal antimicrobial resistance rates are low, and an oral treatment regimen comprising amoxicillin, probenecid and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.

Results

A summary of the proportion of isolates with decreased susceptibility to ceftriaxone, and the proportion resistant to azithromycin, penicillin, and ciprofloxacin for Quarter 1 2017 are shown in **Table 1**.

Table 1:

State or Territory	Number of isolates tested Q1, 2017	Decreased Susceptibility		Resistance					
		Ceftriaxone MIC $\geq 0.06-0.125$ mg/L		Azithromycin MIC ≥ 1.0 mg/L		Penicillin* MIC ≥ 1.0 mg/L		Ciprofloxacin MIC ≥ 1.0 mg/L	
		n	%	n	%	n	%	n	%
Australian Capital Territory	33	0	0	0	0	3	9.1	4	12.1
New South Wales	801	9	1.1	76	9.5	259	32.3	228	28.5
Queensland	339	3	0.9	7	2.1	83	24.5	63	18.6
South Australia	104	2	1.9	21	20.2	39	37.5	30	28.8
Tasmania	23	0	0	5	21.7	10	43.5	10	43.5
Victoria	638	10	1.6	107	16.8	220	34.5	219	34.3
Northern Territory Urban & Rural	17	0	0	1	5.9	3	17.6	4	23.5
Northern Territory Remote	38	0	0	0	0	0	0	0	0
Western Australia Urban & Rural	180	3	1.7	12	6.7	31	17.2	28	15.6
Western Australia Remote	42	0	0	0	0	0	0	0	0
AUSTRALIA	2215	27	1.2	229	10.3	648	29.3	586	26.5

Table 1: Gonococcal isolates showing decreased susceptibility to ceftriaxone and resistance to azithromycin, penicillin, and ciprofloxacin, Australia, 1 January to 31 March 2017, by State or Territory

* Penicillin resistance includes MIC value of ≥ 1.0 mg/L, or penicillinase production.

In the first quarter of 2017 the proportion of isolates with ceftriaxone decreased susceptibility in Australia was 1.2%, and this was lower than the annual proportion for 2016. Compared with the annual data for 2016, in Quarter 1 2016, Victoria, and South Australia and urban Western Australia reported a slight increase in the proportion of *Neisseria gonorrhoeae* isolates with decreased susceptibility to ceftriaxone, New South Wales, Queensland, Tasmania and the Australian Capital Territory reported a decrease in the proportion of *N. gonorrhoeae* isolates with decreased susceptibility to ceftriaxone, while the other states reported similar results. ⁽¹⁾

The category of ceftriaxone decreased susceptibility as reported by the AGSP includes the MIC values 0.06 and 0.125 mg/L, and the national trend since 2010 is shown in **Table 2**.

Ceftriaxone MIC mg/L	2010	2011	2012	2013	2014	2015	2016	2017 Q1
0.06	4.80%	3.20%	4.10%	8.20%	4.80%	1.70%	1.65%	1.20%
0.125	0.10%	0.10%	0.30%	0.60%	0.60%	0.10%	0.05%	0

Table 2: Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone MIC 0.06–0.125 mg/L, Australia, 2010 to 2016, and 1 January to 31 March 2017.

A summary of ceftriaxone decreased susceptibility strains that were multi-drug resistant (MDR), or isolated from extra genital sites (rectal and pharyngeal) for Quarter 1, 2017 by state or territory, and by sex (male/female) are shown in **Table 3**.

Strains with ceftriaxone decreased susceptibility (CRO DS)									
State or Territory	Total	Multi-Drug Resistant		Males		Females		Extra genital sites	
		n	%	n	%	n	%	n	%
Australian Capital Territory	0	0	0	0	0	0	0	0	0
New South Wales	9	1	11.1	7	78	2	22	2	22
Queensland	3	3	100	2	67	1	33	2	67
South Australia	2	0	0	1	50	1	50	0	0
Tasmania	0	0	0	0	0	0	0	0	0
Victoria	10	6	60	9	90	1	10	7	70
Northern Territory Urban & Rural	0	0	0	0	0	0	0	0	0
Northern Territory Remote	0	0	0	0	0	0	0	0	0
Western Australia Urban & Rural	3	2	67	3	100	0	0	2	67
Western Australia Remote	0	0	0	0	0	0	0	0	0
AUSTRALIA	27	12	44.4	22	81.5	5	18.5	13	48.1

Table 3: Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone (MIC 0.06–0.125 mg/L) that showed multiply drug resistance (MDR), isolated from extra genital sites, and by sex, Australia, 1 January to 31 March 2017.

Azithromycin

In the second quarter of 2017, the proportion of isolates with resistance to azithromycin in Australia was 11.0%, slightly higher than in Quarter 1 2017 (10.3%), more than double the proportion reported nationally for 2016 (5.0%), and more than four times the level reported in Australia for 2013-2015 (2.1%-2.6%).¹ In 2016 the highest incidence of azithromycin resistance was reported from South Australia (19.5% in 2016, compared with 2.8% in 2015), where an outbreak of strains with low level azithromycin was reported.¹ As a result subsequent changes to treatment guidelines were made.² In 2016 increases in azithromycin resistance were also reported from Victoria and urban Western Australia.¹ Globally there have been increasing reports of azithromycin resistance in *N.gonorrhoeae*.³

In quarter 1 2017 most states reported isolates with resistance to azithromycin, with the exception of the Australian Capital Territory, remote Northern Territory and remote Western Australia. The states that reported an increase in the proportion of NG isolates with resistance to azithromycin when compared with the annual data for 2016 were Victoria, New South Wales, Queensland and Tasmania. There was a decrease shown in the Australian Capital Territory, while the other states reported similar results from 2016 annually. Ongoing investigations including typing studies are underway in the jurisdictions.

Dual therapy of ceftriaxone plus azithromycin is the recommended treatment for gonorrhoea as a strategy to temper development of more widespread resistance. Patients with infections in extra genital sites, where the isolate has decreased susceptibility to ceftriaxone, are recommended to have test of cure cultures collected. Continued surveillance to monitor *N.gonorrhoeae* with elevated MIC values, coupled with sentinel site surveillance in high risk populations remains important to inform therapeutic strategies, to identify incursion of resistant strains, and to detect instances of treatment failure.

References

1. Lahra MM, Enriquez RP. Australian Gonococcal Surveillance Programme Annual Report, 2016. Communicable Diseases Intelligence *In press*.
2. Lahra MM, Ward A, Trembizki E, Hermanson J, Clements E, Lawrence A, et al. Treatment guidelines after an outbreak of azithromycin-resistant *Neisseria gonorrhoeae* in South Australia. *The Lancet Infectious diseases*. 2017;17(2):133-4.
3. Unemo M. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving *Neisseria gonorrhoeae* continues to challenge. *BMC infectious diseases*. 2015;15:364